Featured Article Why Is My Pet Gaining Weight? Cover Story PetIQ Acquires MYOS to Expand Muscle Health Product expansion Parnell Adds 50 mL PropofolVet Multidose Corporate update PetVivo Ends VetStem Partnership Private equity Artá Capital Invests in Magapor Strategic Acquisition LIMPID Co...
Quick Takeaways: Why It Matters? Parnell’s 50 mL PropofolVet Multidose should help veterinary practices match vial size to procedure volume, cutting waste and improving inventory efficiency while keeping the same propofol use cases and 28-day, no-refrigeration convenience. Marketwise, the ...
Quick Takeaways: Why It Matters? The deal broadens PetIQ’s product mix into a higher-value mobility category that can be cross-sold through retail, e-commerce and distribution channels, potentially increasing average basket size and strengthening PetIQ’s positioning as a branded pet health...
Quick Takeaways: Why It Matters? By terminating the PrecisePRP arrangement with VetStem, PetVivo removes outstanding invoices, royalties and milestone overhangs from a non-core product line, which should simplify the story for investors and management while freeing attention and capital fo...
Quick Takeaways: Why It Matters? The deal strengthens Magapor’s ability to expand beyond its 60+ country footprint by adding growth capital for R&D, commercial expansion and product development in a niche but defensible livestock-reproduction category, while allowing the Mena Gericó fa...
Quick Takeaways: Why It Matters? LIMPID’s acquisition of PetPeotalk turns Kinfora into a richer, behaviour‑driven pet health platform, because it brings in a mature vision‑AI stack (Dogibogi) with real‑world scale, hundreds of millions of labelled behaviour ...
Featured Article Cover Story Product launch Clinical data Retail pharmacy FDA Launches Animal Drug Manufacturing Pilot Regulatory update The FDA’s Center for Veterinary Medicine has launched a pilot program to speed review of animal drug applications when both the finished product and acti...
Quick Takeaways: Why It Matters? Medgene’s launch could be a meaningful de-risking event for cattle producers because it creates the first U.S. prescription vaccine option for a parasite with severe herd-level consequences and no approved treatment, potentially reducing losses from mortali...
Quick Takeaways: Why It Matters? Zoetis’s Portela launch should expand the feline OA market by turning a hard-to-manage, underdiagnosed condition into a more actionable treatment segment, especially because the therapy offers a three-month injectable option that is easier for owners to kee...
Quick Takeaways: Why It Matters? Credelio Quattro appears to have a clear speed-of-kill advantage over Simparica Trio and NexGard Plus, with the studies showing faster and more sustained tick kill through the full monthly dosing interval. That matters because quicker tick death lowers the ...
